openPR Logo
Press release

Pneumonia Testing Market Expected to Claim $1,738 Million, Worldwide, by 2023

02-18-2019 07:47 PM CET | Health & Medicine

Press release from: Allied Market Research

Pneumonia Testing Market

Pneumonia Testing Market

Pneumonia is a complicated infection that affects the lower respiratory tract and is characterized by symptoms such as short breathing, fever, chest pain, nausea, and vomiting. In pneumonia, the air sacs of lungs called as alveoli are filled with fluid or pus that cause inflammation. It is mainly caused by microorganisms such as bacteria, virus, fungi, and parasites and mostly affects people with weakened immune systems and is common in children and older people.

Global Pneumonia Testing Market was valued at $932 million in 2016, and is estimated to reach $1,738 million by 2023, registering a CAGR of 9.2% from 2017 to 2023.

Send Enquiry on this report @ https://www.alliedmarketresearch.com/purchase-enquiry/3776

As per WHO, pneumonia is one of the major factors causing death in children and is estimated to affect approximately 1.2 million children under the age of five years annually. As per WHO, 95% of all pneumococcal episodes occur in children in the developing countries.

The market is expected to witness a steady growth owing to the development of advanced nucleic acid detection tests and advancement in POC testing products. Moreover, rise in awareness about the benefits of early diagnosis among the patient population has increased the number of diagnostic tests in the developing regions such as India and Africa. Moreover, the increase in adoption of molecular diagnostic testing and untapped markets in the developing economies are expected to provide new avenues for the growth of pneumonia testing market in the near future.

Recent advancement in pneumonia testing systems such as the development of enhanced nucleic acid detection tests and advancement in POC tests is the major factor that contributes toward the growth of the pneumonia testing market. Moreover, increase in awareness toward early diagnosis and rise in government expenditures on healthcare fuel the market growth. However, limited detection capability & accuracy of some of the pneumonia testing products and regulatory & economic hurdles hamper the market growth. Conversely, surge in adoption of molecular diagnostic testing and high untapped market potential in the developing economies are anticipated to provide lucrative opportunities for the market.

The global pneumonia testing market is segmented on the basis of market, by method, type, technology, end user, and region. In terms of method, the market is classified into immunodiagnostics, molecular diagnostics, and point-of-care (POC) testing. By type, it is bifurcated into analyzers and consumables. Based on technology, it is categorized into enzyme linked immunosorbent assay (ELISA), immunofluorescence, western blot, polymerase chain reaction (PCR), immunohistochemistry (IHC), and others. Depending on end user, it is divided into hospitals, diagnostic laboratories, homecare, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Request Sample/ TOC Report @ https://www.alliedmarketresearch.com/request-sample/3776

The POC testing segment was the major contributor to the market in 2016, due to multiple benefits offered by this technique such as technological advancements, ease of use, and rapid results. The consumables segment is estimated to register the highest growth rate during the forecast period, owing to the smaller shelf-life of consumables and their frequent usage for pneumonia tests 2017-2023.

Among the end users, diagnostic laboratories occupied the major share of the pneumonia testing market in 2016, due to large number of tests performed for diagnosis of pneumonia.

In 2016, North America accounted for maximum contribution to the total revenue generated, owing to rise in prevalence of pneumonia and technological advancements in various pneumonia testing products. However, Asia is projected to grow at the highest CAGR during the forecast period, owing to increase in investments by major companies in R&D activities.

Key Findings of the Pneumonia Testing Market:

• POC testing is projected to grow at the highest rate during the analysis period.
• Diagnostic laboratories segment generated the highest revenue, and is expected to continue its dominance in future.
• North America dominated global pneumonia testing market in 2016, and is projected to continue its dominance in future.
• China is expected to grow highest in the Asia-Pacific region during the forecast period.
• ELISA was the largest contributor among the technologies segments.

The key companies profiled in the report include Thermo Fisher Scientific Inc., Abbott Laboratories, F-Hoffmann la Roche Ltd., Hologic Inc., bioMerieux, Becton, Dickenson and Company, Bio-Rad Laboratories Inc., Meridian Biosciences, Quest Diagnostics, and Quidel.

Other prominent players in the value chain include AdvanDx, Beckman Coulter, Cepheid, Concile, Diamedix, DiaSorin, Fast-track Diagnostics, SeraCare, and Trinity Biotech.

Buy Now this Report @ https://www.alliedmarketresearch.com/checkout/652918

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pneumonia Testing Market Expected to Claim $1,738 Million, Worldwide, by 2023 here

News-ID: 1597251 • Views: 362

More Releases from Allied Market Research

North America Geogrid Market 2020 Segmentation, Demand, Growth, Trend, Opportuni …
According to the report published by Allied Market Research, the North America geogrid market generated $282.0 million in 2019, and is estimated to reach $408.25 million by 2027, registering a CAGR of 7.0% from 2020 to 2027. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios. Surge in infrastructure development activities across the U.S. and Mexico and superior physical properties
Intravenous Immunoglobulin (IVIG) Market 2020 In-Depth Analysis of Industry Shar …
Global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds
Asthma and COPD Drugs Market Is Expected to Witness a Steady Growth by 2026
"Asthma and COPD Drugs Market by Disease and Medication Class - Global Opportunity Analysis and Industry Forecasts, 2014-2022", projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America
Synthetic Biology Market in Global Industry by Top Companies, Type and Applicati …
Global Synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020). Europe occupies largest share in the global market and would hold-on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014 - 2020. Read Full Report @ https://www.alliedmarketresearch.com/synthetic-biology-market Synthetic biology is at a nascent stage and has recently

All 5 Releases


More Releases for Pneumonia

Global Pneumonia Therapeutics Market 2018 – 2023
Global Pneumonia Therapeutics Market 2018–2023 Poised for xx% Growth Planet Market Research has recently added a market study named Global Pneumonia Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023 with prime importance on the forecast period from 2018 to 2023. The report is an in-depth analysis of the market for pneumonia therapeutics and covers various driving factors, restraints, opportunities and challenges affecting the market’s growth. Pneumonia is an
Pneumonia Drug Development Market Focuses on Top Players (Hospital Acquired Pneu …
Pneumonia Drug Development Market study provides comprehensive data which enhances the understanding, scope and application of this report. Polyamides, polyethylene, nylons, epoxy resins, polysulfones, polyphthalamides, polyesters, and polycarbonates are some key forms of plastics that are employed in electronic components. The insulation properties of plastic account for its in depth use in electrical and electronic components of machines and gadgets. Report Consultant has introduced a new report titled as Global Pneumonia
Pneumonia Testing Market Opportunity Analysis, 2018-2026
Pneumonia is a lung infection caused by bacteria, viruses or fungi, primarily affecting the small sir sacs known as alveoli. The most common bacterial type that causes pneumonia is Streptococcus pneumoniae. The symptoms for pneumonia include, fever, chills, cough, shortness of breath and fatigue. To detect whether, a person has pneumonia are blood tests, chest X-ray, pulse oximetry, and Sputum test. Further, if the patients is older than age 65,
Hospital-acquired Pneumonia Drugs Market: to reach over by 2020
Hospital-acquired Pneumonia Drugs Market: Overview Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of
Global Pneumonia Market: Industry Analysis, outlook and Forecast by 2025
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “Global Pneumonia Market Report 2018” which provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering U.S, and Europe along with the global market. The report profiles key players of the market including Merck & Co. Inc., Allergan
Pneumonia Diagnostics Market worth US$ 685 Mn by 2027
The World Health Organization estimates that pneumonia accounted for 16% of all deaths of children below the age of 5 years – more than 920,000 in 2015. The WHO states that the cost of pneumonia antibiotic treatment in the same year for child survival and newly born babies is roughly US$ 110 million annually. Therefore, there is a pressing need to analyse the pneumonia diagnostics market. In an upcoming report